Full-Time

Product Portfolio & Digital Marketing Manager

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Reading, UK

Hybrid

Three on-site days per week (Tue, Wed, Thu) required.

Category
Growth & Marketing (1)
Required Skills
Product Management
Data Analysis

Get referred to Intuitive Surgical

See people who can refer or advise you

Requirements
  • Bachelor’s degree in life science or business discipline.
  • Chartered Institute of Marketing or Advanced Diploma preferred.
  • 8+ year’s experience within a medical device or therapeutic company.
  • 4+ years of Clinical/Product marketing experience within a medical device or therapeutic company.
  • Proven ability to effectively position, launch and message product/procedure.
  • Demonstrated ability to work creatively, prioritize and smoothly manage goals and initiatives with competing priorities.
  • Strong commercial acumen to drive product adoption.
  • Self-starter with ability to problem solve and establish solutions in a high-growth and fast-paced environment.
  • Excellent verbal/written communication and presentation skills in English.
  • Strong interpersonal skills across multiple constituents.
  • A keen ability to manage projects, keeping budgeting, organizing, prioritizing and coping with multiple tasks.
  • Strong knowledge of the MS Office product suite.
  • Ability to travel 20-30%. International travel required.
  • The role will be based in Winnersh with office days on Tue, Wed & Thu.
Responsibilities
  • Build and leverage product management skillsets to manage the existing da Vinci Systems, Advanced Technology, I&A and Digital portfolios.
  • Create go-to-market strategies for new products within multiple surgical specialties through close collaboration with the Clinical Marketing, Sales leadership and Training teams on launch strategies and tactics to increase utilization.
  • Integrate the digital portfolio into the commercial teams, to drive awareness and adoption of the entire Intuitive Ecosystem in alignment with business goals.
  • Engage key customers to create and develop reference centers to accelerate technology adoption and utilization of da Vinci systems, Advanced Technologies and Digital solutions.
  • Create clinical and economic reference stories (QTIs) and marketing collateral that articulates the value proposition associated with Intuitive’s technologies.
  • Develop analytical, scalable tools to monitor the portfolio, competition, and opportunities, in collaboration with the Sales Operations Team, to leverage data that informs marketing and sales strategies and opportunities.
  • Identify and scale best demonstrated practices through Key Opinion Leaders and the Field Sales team to improve regional variation in technology adoption and utilization.
  • Identify and develop Product Champions for existing and newly launched products across surgical specialties.
  • Collaborate with Key Opinion Leaders and European Product Marketing to develop localized value propositions and messaging for Intuitive’s technologies.
  • Partner with European and Regional Marketing and Sales at conferences and tradeshows, Executive Education Events, Market Development Events, and Key Customer events, to deliver impactful product demonstrations (test-drives), technology presentations, and ensure the key product messaging is included in Intuitive-sponsored presentations and customer interactions.
  • Grow Energy and Stapling utilization across the UK and Ireland and support sales by implementing new sales tools and collateral.
  • Develop and maintain procedural knowledge and key surgeon relationships by attending cases and collaborating with Regional and EU Marketing.

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. da Vinci placements rose 24% in the latest quarter.[recent news]
  • da Vinci 5’s premium workflow features support hospital upgrade demand.[6]
  • Ion and cardiac expansion broaden Intuitive beyond core soft-tissue surgery.[4][8]

What critics are saying

  • U.S. procedure growth slowed to 12%, pressuring recurring instrument volume.[recent news]
  • The 2027 extended-use program targets lower customer costs, risking revenue compression.[recent news]
  • A 40.8x earnings valuation leaves little room for execution misses.[recent news]

What makes Intuitive Surgical unique

  • da Vinci and Ion anchor Intuitive’s robotic-assisted minimally invasive care platform.[4][15]
  • Recurring revenue comes from instruments, accessories, service, and training.[4][7]
  • da Vinci 5 adds force feedback, analytics, and remote software updates.[6]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 7th, 2026
Intuitive Surgical emerges as dark horse in anti-obesity market as surgery outperforms GLP-1 drugs

Intuitive Surgical could emerge as a dark horse in the anti-obesity market as bariatric surgery proves more effective than GLP-1 drugs for long-term weight loss. A recent study of over 50,000 patients found surgery patients lost an average of 58 pounds after two years, compared to just 12 pounds for those using GLP-1 medications. The study also showed surgery delivers more sustainable results. Gastric bypass patients maintain around 52% of their excess weight loss after 10 years, whilst GLP-1 users often regain all lost weight after stopping treatment. Intuitive's da Vinci surgical system offers minimally invasive bariatric surgery options. The company generated $10.1 billion in revenue last year, up from $8.4 billion, with profit margins around 28%. Despite shares falling over 20% this year, the company's position in surgical innovation makes it a compelling long-term investment.

Yahoo Finance
Mar 29th, 2026
Intuitive Surgical shares drop 19% YTD, but analysts see 15% upside potential

Intuitive Surgical has experienced recent share price weakness, declining 3% in one day with negative returns over the past week, month and three months. The stock currently trades at $452.66, down 10.1% over one month and 19.45% year-to-date, though three-year total shareholder returns remain strong at 77.19%. The medical technology company reports annual revenue of $10.1 billion and net income of $2.9 billion, maintaining a dominant position in minimally invasive surgical technology. According to one valuation analysis, Intuitive Surgical's fair value sits at $532.46, suggesting the stock is undervalued by approximately 15% at current levels. The analysis projects 12% annual revenue growth over the next five years, supported by recurring revenues from spare parts and software licences, with profit margins expected to reach 30% from the current 28.6%.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical shares up 23% after Jim Cramer's buy recommendation

Intuitive Surgical shares rose 23% following Jim Cramer's recommendation on CNBC's Squawk on the Street in June 2025, where he urged investors to "just go buy ISRG". The medical robotics company experienced a 27% surge in October after reporting third-quarter earnings that beat analyst estimates. Revenue reached $2.51 billion against expectations of $2.40 billion, whilst adjusted earnings per share hit $2.40 versus the predicted $1.98. However, the stock declined 2.7% in January 2026 after Intuitive Surgical released preliminary fourth-quarter results, citing concerns that Medicaid funding cuts and competing products could slow growth of its robotic surgical systems. Despite the recent setback, shares remain up significantly since Cramer's initial endorsement, though they're down 7.8% over the past year.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical faces tariff headwinds and rising competition despite 19% revenue growth to $2.87B

Intuitive Surgical faces headwinds from tariffs and increased competition in the robotic-assisted surgery market, yet its fundamentals remain strong. The medical device company reported fourth-quarter revenue growth of 19% to $2.87 billion, whilst adjusted earnings per share rose 14.5% to $2.53. Procedures using its da Vinci surgical system increased 17%, with the installed base growing 12% to 11,106 units. However, the stock trades at 47.6 times forward earnings, compared to the healthcare sector average of 17.1. New competition is emerging, with Medtronic's Hugo system recently cleared and Johnson & Johnson expected to launch its own device soon. Despite these challenges, Intuitive Surgical maintains advantages through switching costs and extensive real-world data, whilst the underpenetrated robotic-assisted surgery market offers long-term growth potential.

Yahoo Finance
Mar 24th, 2026
ISRG maintains 37% operating margins in Q4 despite 95 bps tariff drag

Intuitive Surgical maintained a 37% operating margin in Q4 despite tariffs creating a 95 basis point drag, alongside higher facility costs and unfavourable product mix from newer platforms like da Vinci 5 and Ion. The company offset these pressures through product cost reductions, component savings and manufacturing efficiencies. Procedure growth of 18% in Q4 and recurring revenue now comprising 81% of total revenues provided operating leverage. Management's 2026 gross margin guidance of 67-68% suggests continued stability, even as tariff headwinds are expected to increase to roughly 1.2% of revenues. Meanwhile, Boston Scientific expanded adjusted operating margins by 100 basis points to 28% in 2025, though tariffs will offset favourable product mix in 2026. The company expects 50-75 basis points operating margin expansion in 2026 through scale efficiencies and supply-chain optimisation.